Supplemental Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Ivana Gojo, Jan H. Beumer,Keith W. Pratz,Michael A. McDevitt,Maria R. Baer, Amanda L. Blackford,B. Douglas Smith,Steven D. Gore, Hetty E. Carraway,Margaret M. Showel,Mark J. Levis, Amy E. Dezern, Douglas E. Gladstone,Jiuping Jay Ji, Lihua Wang, Robert J. Kinders,Marie Pouquet, Ismail Ali-Walbi,Michelle A. Rudek,Weijie Poh,James G. Herman,Larry M. Karnitz,Scott H. Kaufmann,Alice Chen,Judith E. Karp

crossref（2023）

引用 0|浏览0

暂无评分

摘要

Table S1. Changes in Proportion (%) of γH2AX-Positive Cells in Peripheral Blood upon Veliparib and Veliparib/Temozolomide Treatment Figure S1. FANCD2 monoubiquitination following ex vivo melphalan treatment of patient bone marrow cells Figure S2.Pretreatment levels of PARP1 and MGMT Figure S3.Pretreatment MGMT promoter methylation in patient peripheral blood (PB) or bone marrow (BM) AML cells Figure S4. PARP inhibition in peripheral blood cells

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要